FOXP1蛋白在弥漫性大B细胞淋巴瘤中的表达及预后意义  

Expression of FOXP1 in diffuse large B-cell lymphoma and its relationship with prognosis

作　　者：张亚楠[1] 刘汉锋[1] 

机构地区：[1]广西医科大学第一附属医院西院肿瘤内科,南宁530007

出　　处：《重庆医学》2015年第17期2368-2370,2373,共4页Chongqing medicine

基　　金：广西壮族自治区卫生厅课题基金资助项目(S200803)

摘　　要：目的探讨叉头框转录蛋白1（FOXP1）在弥漫性大B细胞淋巴瘤（DLBCL）组织中的表达及其与临床病理特征和预后的关系。方法收集2008年1月至2013年12月存档的40例DLBCL患者的石蜡标本,采用免疫组织化学方法检测DLBCL组织中FOXP1的表达情况,分析其与患者临床病理特征及经R-CHOP方案治疗后的临床预后关系,另以40例反应性增生淋巴结组织作为对照。结果40例DLBCL组织中FOXP1阳性表达率为50.0%（20/40）,显著高于对照组17.5%（7/40）,χ2=9.488,P=0.002。其中生发中心（GCB）型DLBCL为14.3%（2/14）,非生发中心（non-GCB）型为69.2%（18/26）,χ2=10.898,P=0.01。FOXP1的表达与乳酸脱氢酶（LDH）水平、B症状、国际预后指数（IPI）、病理分型密切相关（P〈0.05）。Kaplan-Meier显示FOXP1阳性表达者的中位无病生存期（PFS）和中位总生存期（OS）较阴性表达者缩短（P〈0.05）。单因素相关分析表明,临床分期、IPI评分、病理分型及FOXP1的表达与患者生存期（PFS和OS）均相关（P〈0.05）;多因数回归分析显示临床分期[（RR=1.103,95%CI：0.002-2.740,P=0.001）,（RR=0.984,95%CI：0.019-2.666,P=0.002）]和FOXP1的表达[（RR=0.315,95%CI：0.035-0.965,P=0.042）,（RR=0.385,95%CI：0.119-0.834,P=0.020）]是PFS和OS独立的预测因素。结论FOXP1高表达于non-GCB型DLBCL,且可能是DLBCL的一个独立预后指标,提示预后不良。Objective To investigate the clinical and prognostic significance of forkhead box protein1（FOXPl）expression in diffuse large B-cell lymphoma（DLBCL）,and its relationship with prognosis and clinicopathological features.Methods Immunohistochemistry was performed to determine the expression of FOXP1 in 40DLBCL tissues from January 2008 to December 2013 and analyze its the correlations with clinicopathological features and prognosis（rituximab,cyclophosphamide,doxorubicin,vincristine and prednisone,R-CHOP）.In addition,lymph reactive hyperplasia cases（n=40）were chose as contrl group.Results All of the 40 DLBCL patients,50%（20/40）were showed FOXP1 positive expression,however,which was17.5%（7/40）in control group,the differences between them was statistically significant（χ2=6.111,P=0.013）.FOXP1 positive expression in non-germinal center B cell like（non-GCB）DLBCL（18/24,69.2%）was significantly higher than that in germinal center B cell like（GCB）DLBCL（2/14,14.3%）,χ^2=10.898,P=0.01.FOXP1 expression was associated with LDH,B symptom,international prognostic index（IPI）factor score and pathologic types（P〈0.05）.Kaplan-Meier demonstrated that the median progress free survival（PFS）and overall survival（OS）in FOXP1 positive expression patients were shorter than in FOXP1-negative cases.Univariate analysis showed that clinical stages,IPI factor scores,pathological type and FOXP1 expression were prognostic factors of PFS and OS.Meanwhile,Multivariate regression analysis indicated that clinical stages[（RR=1.103,95%CI：0.002 to 2.740,P=0.001）,（RR=0.984,95%CI：0.019 to 2.666,P=0.002）]and FOXP1 expression [（RR=0.315,95%CI：0.035 to 0.965,P=0.042）,RR=0.385,95%CI：0.119 to 0.834,P=0.020）]were independent prognosis indicators for PFS and OS.Conclusion Compared to GCB DLBCL,FOXP1 was more expressed in non-GCB DLBCL.FOXP1 probably is a prognostic factor of PFS and OS for DLBCL,FOXP1 positive may indicate poor outcome.

关 键 词：叉头转录因子类 淋巴瘤 大B细胞 弥漫性 预后 

分 类 号：R733.1[医药卫生—肿瘤]